Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000323

Purpose

The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.

Condition	Phase
Cocaine-Related Disorders	Phase I

Study Type:	Observational
Study Design:	Screening
Official Title:	Therapeutic Potential of Kappa-Opioids Against Cocaine

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:	10
Study Start Date:	July 1996
Estimated Study Completion Date:	December 1998

Eligibility

Criteria

Inclusion Criteria:

opiate experienced, healthy

Exclusion Criteria:

physical dependence on opioids, barbiturates or alcohol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000323

Locations

United States, Maryland
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823

Sponsors and Collaborators

Investigators

Principal Investigator:

Sharon Walsh, Ph.D.

Johns Hopkins University

More Information

No publications provided

Study ID Numbers:	NIDA-10753-1, R01-10753-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000323 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

ClinicalTrials.gov processed this record on November 27, 2009